FNCH News

The IPO market stayed busy this past week, with 11 IPOs raising $3.0 billion. The week’s IPOs were joined by 24 SPACs that raised $8.4 billion. New filers continued to fill the IPO pipeline, with 8 IPOs and 46 SPACs submitting initial filings. Chinese IoT platform developer Tuya (TUYA) priced above the range to raise $915 million at an $11.8 billion...read more

Finch Therapeutics Group, a Phase 3-ready biotech developing microbiome therapeutics, raised $128 million by offering 7.5 million shares at $17, the high end of the range of $15 to $17. The company offered 1.3 million more shares than anticipated. Finch is a microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally...read more

Finch Therapeutics Group, a Phase 3-ready biotech developing microbiome therapeutics, announced terms for its IPO on Monday. The Somerville, MA-based company plans to raise $100 million by offering 6.3 million shares at a price range of $15 to $17. At the midpoint of the proposed range, Finch Therapeutics Group would command a fully diluted market value of $751 million. ...read more

Finch Therapeutics Group, a Phase 3-ready biotech developing microbiome therapeutics, filed on Friday with the SEC to raise up to $100 million in an initial public offering. Finch is a microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs. Its lead candidate, CP101, delivers a complete...read more